|Bid||61.48 x 300000|
|Ask||62.12 x 300000|
|Day's range||61.16 - 61.16|
|52-week range||39.41 - 112.06|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||01 May 2023 - 05 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...
According to the National Center for Advancing Translational Sciences, the average period from therapy discovery to Food and Drug Administration (FDA) approval is 14 years and costs $1 billion. Clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are growing because the increasing price of developing, testing, manufacturing, and marketing therapies has made it more important that pharmaceutical companies speed the process along with fewer failures. Rather than doing all the clinical trial work or manufacturing work in-house, more healthcare companies are turning to CROs and CDMOs to reduce overhead and expedite bringing therapies to market.
Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.